NEWS
CELLIST SHEKU BECOMES JDRF AMBASSADOR
DEXCOM AQUIRES TYPEZERO
JDRF, the leading global organisation
funding type 1 diabetes research, has
appointed internationally renowned
cellist Sheku Kanneh-Mason as a global
ambassador. The 19 year-old British cellist
captured the world's attention during
his performance at the Royal Wedding
of Prince Harry and Meghan Markle.
Kanneh-Mason was diagnosed with Type
1 diabetes at the age of 12, five years
before he won BBC Young Musician 2016
and made his mark as one of the brightest
young stars in classical music, all the while
balancing his blood glucose levels before
he performs.
"Managing my diabetes does provide
an extra challenge before I perform. Most
musicians don't have to think about
avoiding hypos," he explains. "But playing
at the Royal Wedding was awesome and
I'm glad I can help raise awareness of
the condition and of the Type 1 diabetes
charity, JDRF."
As JDRF Global Ambassador,
Kanneh-Mason will help to highlight
JDRF's international research programme
and lend his voice to enhance fundraising,
advocacy and education efforts in the fight
against Type 1 diabetes. He is currently
studying at the Royal Academy of Music
and is passionate about making classical
music accessible to all.
www.jdrf.org.uk
As reported by Business Insider in late
August, Dexcom announced that it
had acquired TypeZero Technologies,
Inc. TypeZero's offering includes the
inControl diabetes management system,
designed to provide personalized
diabetes management solutions including
technology to automatically adjust and
regulate insulin delivery.
Dexcom, TypeZero and the University
of Virginia have had a longstanding
relationship working towards developing
important technologies for diabetes
management, including inControl for
integration with both automated insulin
delivery (AID, in other words insulin
pumps) and smart insulin pens.
Steve Pacelli, Dexcom's Executive
Vice President of Strategy & Corporate
Development, commented, "TypeZero
is a great fit for Dexcom as we look to
deliver a growing set of tools to both
our insulin delivery partners and our
customers. Combined with best-inclass CGM technology,
we believe
TypeZero's technology and strong team
will accelerate our efforts to further
differentiate Dexcom's portfolio."
Chad Rogers, TypeZero's CEO,
added, "For the last several years, our
company has been committed to creating
diabetes management products that
simplify the life of a person with diabetes.
As part of Dexcom, we will continue to
embrace the mission to empower people
with diabetes through innovation."
Dexcom expects to support the first
commercial launch of an AID system
using the inControl algorithm in 2019.
www.dexcom.com/en-gb
American Dexcom users
Mark Pugliese and Matt
Robinson reach new
heights on the top of
Mount Kilimanjaro.
Sheku Kanneh-Mason